To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study
The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with these separate chemotherapy regimens. Study sites in North America and the European Union are expected to participate in this trial. The first patient was enrolled at Fox Chase Cancer Center in Philadelphia, PA.
Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.
